Metraipolis › archive › dc_4ea5dc673e25
Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective… — Europe PMC PMID:42089693
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42089693
- DOI
- 10.2340/ao.v65.45460
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T15:38:28.136Z
- SHA-256 of the archived text
c888f021572431bb15143ef8e074718d442c98a2210e4b83f0229b36fee1bb48- Stable URL of this page
https://metraipolis.com/documento/dc_4ea5dc673e25
How to cite
Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective… — Europe PMC PMID:42089693 — Europe PMC (en), https://europepmc.org/article/MED/42089693 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_4ea5dc673e25 (Metraipolis archive dc_4ea5dc673e25, sha256 c888f021572431bb15143ef8e074718d442c98a2210e4b83f0229b36fee1bb48)
BibTeX
@misc{dc4ea5dc673e25,
title = {Incidence and impact of pseudoprogression and mixed responses in metastatic renal cell carcinoma patients treated with ipilimumab/nivolumab: a retrospective… — Europe PMC PMID:42089693},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42089693},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_4ea5dc673e25; sha256 c888f021572431bb15143ef8e074718d442c98a2210e4b83f0229b36fee1bb48},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42089693. Agents can read the archived copy with the MCP tool read_document.